stsa-1005
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 27, 2021 (NCT05085197)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2INHIBITOR
inhibitor - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05559125 | Phase 1 | Nov 8, 2022 | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05085197 | Phase 1 | Oct 27, 2021 | Staidson Biopharma Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals Co., Ltd | For profit | 1 | 1 | 1 | 2022 |
| Staidson Biopharma Inc. | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1